Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Gain Therapeutics is set to release its Q2 2025 earnings report on August 14th, with analysts predicting an earnings per share (EPS) loss of ($0.17).
• The company's stock is currently trading down 7.5%, with shares opening at $1.55, and it has a market capitalization of $46.46 million.
• HC Wainwright maintains a "buy" rating on Gain Therapeutics, setting a target price of $8.00, while the average price target among analysts is $8.20.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Gain Therapeutics to post earnings of ($0.17) per share for the quarter.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gain Therapeutics Trading Down 0.7%

Shares of NASDAQ:GANX traded down $0.01 during trading hours on Friday, hitting $1.48. 133,249 shares of the company's stock traded hands, compared to its average volume of 288,671. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $3.19. The business has a fifty day moving average price of $1.72 and a 200-day moving average price of $1.92. The firm has a market capitalization of $44.50 million, a P/E ratio of -1.72 and a beta of 0.10. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Thursday, July 3rd. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Gain Therapeutics has an average rating of "Buy" and a consensus price target of $8.20.

Institutional Trading of Gain Therapeutics

A hedge fund recently raised its stake in Gain Therapeutics stock. Geode Capital Management LLC lifted its position in Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) by 2.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 290,462 shares of the company's stock after purchasing an additional 8,251 shares during the period. Geode Capital Management LLC owned 0.97% of Gain Therapeutics worth $523,000 at the end of the most recent quarter. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.